INTS
Intensity Therapeutics, Inc.
There isn't enough reported data to score INTS yet.
INTS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
INTS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
INTS PE Valuation
INTS has no meaningful PE right now: it lost money over the past year.
INTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect INTS's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
INTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$60.75 | +$1.25 |
| Q2 2023 | -$69.50 | -$5.00 |
| Q1 2023 | -$48.00 | +$16.00 |
| Q4 2022 | -$55.50 | +$2.00 |
| Q3 2022 | -$62.00 | -$10.00 |
INTS is still losing money, but far less than before: $15.75 per share over the past year, against $69.50 at its worst in mid-2023.
INTS Quarterly Revenue
INTS's revenue is shrinking: $0 last quarter.
INTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.5M | -$113K |
| Q2 2026 | -$2.3M | +$116K |
| Q1 2026 | -$1.8M | +$163K |
| Q4 2025 | -$2.4M | +$267K |
| Q3 2025 | -$2.4M | +$1.6M |
| Q2 2025 | -$2.5M | +$1.8M |
| Q1 2025 | -$2M | +$2.4M |
| Q4 2024 | -$2.7M | -$1.7M |
INTS has burned cash in almost every quarter: −$9M over the past year, against −$10M the year before.
INTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +20% | +551K shares |
| 1 year | +332% | +2.5M shares |
| 3 years | +2288% | +3.1M shares |
| 5 years | +2288% | +3.1M shares |
INTS has 3M diluted shares, up 332% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
INTS Net Leverage
INTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 13.2 | Oversold |
INTS's weekly RSI is 35 (neutral) and its Stochastic is 13 (oversold).
INTS PE vs Healthcare Sector
INTS has no meaningful PE right now: it lost money over the past year.
INTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.37 | 8% below |
| 20 week MA | $3.94 | 21% below |
| 50 week MA | $5.79 | 46% below |
| 100 week MA | $15.4 | 80% below |
INTS is in a downtrend: it's below all four of its weekly moving averages, and 80% below its 100-week average.
INTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $149.0 | $214.3 | +44% |
| 2024 | $214.3 | $49.3 | -77% |
| 2025 | $49.3 | $9.82 | -80% |
| 2026 YTD | $9.82 | $3.10 | -68% |
INTS has finished lower in two of the last three years. It's down 68% so far in 2026.